Biochemical and biophysical characterizations femto-st of Outer Membrane Vesicles through the SCIENCES & **TECHNOLOGIES NanoBioAnalytical Platform**

Maximova K¹, Pénary M², Legrand D¹, Rouleau A¹, Maes P³, Rageot D³, Taieb F², Martin P², Boireau W¹, Elie-Caille C¹, Oswald E² and Frelet-Barrand A¹

¹ FEMTO-ST Institute, UBFC, CNRS, Besançon, France; ² IRSD, UMR1220, CHU Toulouse, France; ³ CLIPP, Université de Bourgogne, Dijon, France annie.frelet-barrand@femto-st.fr

The Outer-Membrane Vesicles (OMVs) are spherical buds (20-250 nm) that display multiple offensive and defensive functions (Fig 1; [1]). Such versatility makes them an excellent tool for therapy, bioengineering (vaccines, protein production, drug delivery; [2]) and development of new antimicrobial peptides. However, many uncertainties still exist at the level of biogenesis and function mechanisms of these vesicles, hence there is a strong interest for better understanding of their composition, structure and diversity. Major ones

Recombinant OMVs were purified from E. coli laboratory strain BL21 (DE3) overexpressing or not the virulence gene haemolysin F, protein which boost OMVs synthesis [3] (OE-HlyF and Δ - HlyF respectively). In order to compare OMV structure and composition in OE HlyF versus Δ- HlyF, they were biochemically and then biophysically characterized in solution and on biochip using the NanoBioAnalytical platform (NBA) [4]. The latter resides on the combination of two label free techniques: the Surface Plasmon Resonance (SPR) and the Atomic Force Microscopy (AFM), which allow a fine characterization of nanoscale biological objects captured on the surface of a biochemically functionalized biochip; it is coupled to mass spectrometry (MS) for a proteomics analysis (Proteomics Platform CLIPP, Dijon).



Bacterial killing Delivery of virulence factors Elicit inflammatory ④ Host-tissue disruption Concentrate toxing

Fig 1: Offensive and defensive functions and prospective applications of OMVs [5]

Methods [3,4]

6500g

• •

89

Culture

37°C, 8 h,

250 rpm

Biochemical characterizations





On-chip characterization via NBA platform

Sharing of resistance

Enhanced biofilm

Relieving stress

6) Trapping AMPs

Nutrient acquisition

determinants

formation



Fig 5: SPRi sensorgrams of specific capture by antibody α -*E. coli* of OE HlyF (left) and Δ - HlyF (right) on a multiplex gold biochip. C-: negative control (irrelevant IgG). N=2

 \rightarrow OMVs are specifically captured on a biochip via specific antibodies





NO 10 min, 4°C PREPARAT

filtration 0,45µm+ 150000g, 3h, 4°C



METR

OLOGY

Western

Blot

TRPS







 \rightarrow OE-HlyF OMVs are larger than Δ -HlyF and OMVs concentration is compatible with biophysical approaches on biochip

→ DLS data are in accordance with TEM and AFM results [5] but small OMVs can not be evaluated by TRPS due to the cut-off of the technique (80 nm)

MS analysis (nanoLC-MS/MS) in solution



Fig 4 : Venn diagram of proteomic analysis of OMVs from both types of samples (500 ng of proteins)

- \rightarrow Most of proteins are common to both types of OMVs
- \rightarrow OmpA is among the 104 common proteins \rightarrow potential candidate for SPRi experiments
- \rightarrow Absence of HlyF due to databases used for analysis

Fig 6: AFM imaging in air in contact mode of OMVs captured on α-*E.coli*. (A-B): Error signal images of OE HlyF (A) and Δ-HlyF (B); (C-D): profile sections of selected zones. The particles are fixed with 0.5% glutaraldehyde.



Fig 7: Particles size distribution histogram calculated from AFM imaging (2000 particles measured)

Fig 8: Box and whisker plot of OMVs effective diameter defined from AFM imaging.

 \rightarrow Similar size distribution for OMVs from OE-HlyF and Δ -HlyF ; 90% of OMVs between 25 and 70 nm / 1% larger than 100 nm

Conclusion



✓ Adequation of size determination of OMVs in solution and through biochip specific capture \checkmark Data from these studies are in accordance with previous results obtained by TEM [3] Complementary analysis is required for completed characterization of OMVs (lipidomics,...) ✓ NBA platform suitable for other bacterial EVs characterization

References

[1] Schwechheimer C, Kuehn MJ (2015) Nat Rev Microbiol. 13:605-19. [2] Acevedo R et al. (2014) Front Immunol. 5:121. [3] Murase et al. (2016) J Infect Dis. 213:856-65 [4] Obeid S et al. (2016) Biosens Bioelectron. pii: S0956-5663(16)30856-9. [5] Jan (2017) Frontiers in Microbiology 8:1053.

Biochemical and biophysical characterizations of other recombinant OMVs to study functions of protein(s) implicated in OMVs biogenesis

Perspectives

- Analysis of samples from patients suffering from bacterial infection and sepsis
- Determination of function/pathogenicity of OMVs











